Dry Eye Syndrome Treatment Market Size, Share & Trends Analysis Report By Type (Evaporative, Aqueous Deficient), By Drug, By Product, By Dosage Form, By Sales Channel, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

0.Dry Eye Syndrome Treatment Market Trends

The global dry eye syndrome treatment market size was estimated at USD 5.92 billion in 2023 and is projected to grow at a CAGR of 7.97% from 2024 to 2030. The market is driven by the rising prevalence of DES due to factors such as aging and increased screen time, along with growing awareness of the condition. Advancements in treatment options, including new drug formulations and innovative therapies, further boost market growth. Increased consumer preference for accessible and effective treatments, both prescription and over the counter, alongside improvements in diagnostic tools and healthcare infrastructure, also contribute significantly. In addition, the expansion of online pharmacies and the introduction of novel therapies enhance market accessibility and revenue potential.

The Dry Eye Report published  in February 2024 highlights key trends and insights that state approximately 16 million Americans estimated to be affected by dry eye diseases. The report shows a significant increase in clinical focus on DED, with 43.39% of practices dedicating more attention to it over the next year. Respondents, primarily private practitioners, estimate that 67.55% of their patients suffer from DED, though only 46.38% are officially diagnosed.

Confidence in diagnosing and managing DED is high among optometrists, with a shift towards holistic and individualized treatment approaches. The report emphasizes the need for comprehensive patient screening and management, noting a decrease in the expansion of dry eye services despite rising prevalence. The report fosters market expansion by increasing awareness of DED and highlighting its growing prevalence, driving demand for advanced diagnostics and treatments. Additionally, the emphasis on innovative solutions and comprehensive patient care aligns with rising demand, propelling market growth and creating opportunities for industry advancements.

Moreover, the introduction of a novel treatment for DED significantly impacts market growth. By addressing unmet needs in patients who do not respond to conventional therapies, this innovative formulation offers rapid action and improved tolerability. Such advancements are expected to drive increased adoption among ophthalmologists and expand patient access to effective treatments. For instance, in August 2023, Novaliq GmbH's CyclASol (ciclosporin eye drops) received the European Medicines Agency's acceptance for marketing authorization, targeting DED as unresponsive to tear substitutes. Utilizing Novaliq’s novel, water-free EyeSol technology, CyclASol offers a unique, non-preserved formulation that avoids common irritants. The drug has demonstrated safety and efficacy in six clinical studies with 1,575 patients. CyclASol is already FDA-approved in the U.S. under the name VEVYE. Novaliq’s technology also supports MIEBO and VEVYE, addressing significant unmet needs in ocular therapeutics. This strategy positions the new product as a key player in the ocular therapeutics market, potentially capturing a substantial market share and accelerating overall growth in the sector.

In addition, the acceptance of ophthalmic solutions by the regulatory body is poised to significantly impact the market by introducing a novel treatment option for patients unresponsive to traditional tear substitutes. For instance, in August 2023 , Novaliq announced that the European Medicines Agency had accepted its marketing authorization application for CyclASol. This novel treatment, designed for patients with DED who do not benefit from tear substitutes, uses a unique water-free technology. The EMA’s Committee for Medicinal Products for Human Use (CHMP) will review the application for approval across all EU member states. CyclASol has already been approved in the U.S. under the name VEVYE. Such initiative attracts investment boosts market competition and expands the range of available treatments, thereby accelerating overall market growth and fostering a dynamic healthcare landscape.

Market Concentration & Characteristics

The market is characterized by a high degree of innovation, particularly with advancements such as novel water-free technology. This approach sets itself apart from traditional treatments by eliminating the need for water, preservatives, oils, and surfactants. Such a unique formulation enhances patient tolerance and efficacy by avoiding common irritants. By incorporating ciclosporin into this advanced delivery system, the treatment targets both symptoms and underlying inflammation more effectively, potentially transforming options for patients unresponsive to conventional tear substitutes.

Regulations significantly impact the market by shaping product development, approval processes, and market access. Stringent regulatory requirements ensure that treatments meet safety and efficacy standards, which can drive innovation but also extend time-to-market and increase costs. For instance, new drug applications and clinical trials must comply with rigorous protocols, influencing the introduction of novel therapies. Regulatory approvals, such as those from the FDA and EMA, are crucial for market entry and can affect competitive dynamics. Overall, regulations ensure high-quality treatments and impact market dynamics and timelines.

The level of mergers and acquisitions (M&A) activities in the market is high, driven by a competitive landscape and the need for innovation. Pharmaceutical and biotech companies are actively acquiring or merging with firms that offer promising new treatments or advanced technologies. These M&A activities help companies expand their portfolios, enhance R&D capabilities, and gain market share. For instance, in September 2023, Bausch + Lomb completed the acquisition of XIIDRA (lifitegrast ophthalmic solution) 5% from Novartis for up to USD 2.5 billion. This acquisition positions Bausch + Lomb to become a major player in the prescription dry eye segment. In addition to XIIDRA, the company has acquired MIEBO (perfluorohexyloctane ophthalmic solution) and other ophthalmology assets, including the investigational compounds libvatrep and AcuStream technology. These moves are expected to enhance Bausch + Lomb's market position and address the needs of millions affected by dry eye disease.

Product expansion in the market is high, driven by advancements in therapeutic technologies, and rising consumer demand for effective solutions. Innovations such as water-free formulations and novel drug delivery systems enhance treatment efficacy and tolerability. Additionally, growing awareness and improved diagnostic capabilities contribute to a broader market. The expansion of online pharmacies and availability of new treatments further boost product accessibility and market potential. These factors collectively propel the growth and diversification of DES treatment offerings.

The global expansion of the market is marked by increasing international market presence. Companies are actively pursuing entry into new regions through regulatory approvals and strategic partnerships. This global expansion is driven by increasing awareness and advancements in diagnostic tools. By targeting underserved areas, companies are enhancing market accessibility and improving patient outcomes on a global scale, demonstrating a broader commitment to meeting diverse regional needs.

Type Insights

The evaporative dry eye syndrome segment held the largest revenue share of 82.5% in 2023, due to its prevalent and complex nature, driven by increased exposure to environmental factors and lifestyle choices. This type of dry eye results from inadequate tear film stability caused by excessive evaporation, often exacerbated by factors like prolonged screen use, air conditioning, and exposure to pollutants. The growing prevalence of these risk factors, coupled with advancements in diagnostic and treatment technologies, fuels its dominance. Market growth is further supported by the development of specialized treatments targeting tear film stability and evaporation control, making evaporative dry eye a primary focus in both research and therapeutic interventions within the dry eye syndrome market.

Aqueous deficient dry eye syndrome is projected to grow significantly from 2024 to 2030 due to increasing awareness and better diagnostic capabilities. This type characterized by inadequate tear production, often leads to more severe symptoms and requires targeted treatments. The rising prevalence of autoimmune diseases, such as Sjögren’s syndrome, which commonly causes aqueous deficiency, is contributing to this growth. Advances in treatment options and a broader range of therapeutics specifically addressing aqueous deficiency are also driving market expansion.

Drug Insights

The Restasis segment held a significant revenue market share of 25.14% in 2023, due to its proven efficacy, long-standing market presence, and significant impact on patient health. Restasis (cyclosporine ophthalmic emulsion) is a prescription eye drop used to treat chronic dry eye disease by increasing tear production in patients whose tear production is suppressed due to inflammation. Developed by Allergan (now part of AbbVie), Restasis has been a trusted treatment for dry eye syndrome since its FDA approval in 2003. It is particularly effective for patients with moderate to severe dry eye, especially those linked to underlying inflammation.

Eysuvis is projected to grow fastest CAGR from 2024 to 2030 due to its innovative formulation and effectiveness in treating dry eye syndrome. As a corticosteroid designed specifically for short-term use, Eysuvis offers rapid relief of inflammation and symptoms associated with dry eye disease. Its distinct advantage lies in its targeted action and minimal side effects compared to other corticosteroids. In addition, Eysuvis addresses unmet needs in patients with more severe cases, contributing to its growing adoption. Strong clinical trial results and positive feedback from both patients and healthcare providers further drive its market growth. Increased awareness and its inclusion in comprehensive treatment regimens support its rapid expansion.

Product Insights

The cyclosporine segment held the largest revenue share of 60.20% in 2023, due to its proven efficacy in treating moderate to severe cases of dry eye disease. As an immunomodulatory drug, cyclosporine addresses the underlying inflammation that contributes to dry eye symptoms, providing long-term relief and improving overall eye health. Its established safety profile and effectiveness have led to widespread adoption among healthcare providers. In addition, cyclosporine's ability to enhance tear production and reduce inflammation makes it a preferred choice for patients who do not respond well to other treatments. The availability of cyclosporine in various formulations, including Restasis and the newer Xiidra, further solidifies its market leadership and widespread use.

Topical corticosteroids are projected to grow at the fastest CAGR from 2024 to 2030 due to their potent anti-inflammatory properties and rapid symptom relief. These steroids effectively reduce inflammation and irritation in severe dry eye cases, making them a critical option for patients who do not respond to standard treatments. Their ability to provide quick and significant improvement in symptoms enhances patient satisfaction and drives their adoption. With advancements in formulation that minimize side effects, such as preservative-free options, topical corticosteroids are becoming increasingly attractive. Their growing acceptance among ophthalmologists and improved patient outcomes contribute to their anticipated rapid growth in the market.

Dosage Form Insights

The eye drops segment held the largest revenue share of 38.66% in 2023, due to their widespread use, effectiveness, and ease of application. They offer targeted relief by directly addressing the symptoms of dry eye, such as discomfort and dryness, and are available in various formulations to meet diverse patient needs. Eye drops are preferred for their convenience, quick action, and accessibility, making them a popular choice for both over the counter and prescription treatments. The development of advanced formulations, including preservative-free and novel delivery systems, further enhances their efficacy and tolerability. Additionally, the broad range of options and continual innovation in eye drop products contribute significantly to their market dominance.

Eye solutions are projected to grow fastest from 2024 to 2030 due to their versatile and effective application in treating various severities of the condition. Unlike eye drops, which can vary in viscosity and intended use, eye solutions offer a broader range of formulations, including those with advanced ingredients for enhanced efficacy. Their ability to deliver consistent dosages and address both symptoms and underlying causes makes them increasingly popular among healthcare providers. Additionally, innovations in eye solution formulations, such as those incorporating novel technologies for better absorption and longer-lasting effects, further drive their adoption, fueling rapid market growth.

Sales Channel Insights

The over-the-counter (OTC) segment held the largest revenue share of 61.27% in 2023, due to their accessibility and convenience. OTC products, such as eye drops and lubricating gels, are readily available without a prescription, allowing consumers to manage symptoms easily and promptly. This channel meets the high demand for immediate relief and preventative care, catering to a broad audience who prefer self-medication. OTC products also benefit from widespread retail distribution and online availability, enhancing their reach. Additionally, the continuous innovation and variety in OTC formulations provide effective solutions for various types of dry eye syndrome, further solidifying their leading position in the market.

The prescription segment is expected to witness the fastest growth from 2024 to 2030 due to the increasing complexity of treatment options and the need for tailored therapies. As dry eye syndrome becomes more prevalent and treatment options advance, physicians are increasingly recommending specialized prescription medications that address the specific underlying causes of the condition. These prescriptions often include newer, more effective drugs that require a healthcare provider’s oversight to ensure proper use and to manage potential side effects. Additionally, advancements in prescription treatments, such as innovative formulations and targeted therapies, are driving demand, leading to accelerated growth in this sales channel.

Distribution Channel Insights

The retail pharmacies segment held the largest revenue share of 45.01% in 2023 due to their widespread accessibility and convenience for consumers. These pharmacies serve as key distribution points, offering a range of dry eye treatments, including eye drops, gels, and ointments. Their extensive network ensures that patients can easily find and purchase products without needing a prescription. Retail pharmacies often have knowledgeable staff who can provide guidance and recommendations, enhancing the consumer experience. Additionally, their integration with both physical stores and online platforms boosts accessibility, allowing for quick and efficient purchasing. This broad reach and ease of access make retail pharmacies a dominant channel in the dry eye syndrome market.

Online pharmacies are projected to grow at the fastest CAGR from 2024 to 2030 due to their increasing accessibility and convenience for consumers. The shift towards digital healthcare solutions is driven by the rising preference for online shopping and the ease of obtaining medications without needing to visit physical stores. Online pharmacies offer a broad range of products, including prescription and over-the-counter treatments, often at competitive prices. They also provide discreet access to treatments for sensitive conditions like dry eye syndrome. Additionally, advancements in e-commerce technology and improved online pharmacy regulations are enhancing consumer trust and driving market growth in this channel.

Regional Insights

North America dry eye syndrome treatment market dominated the overall global market and accounted for the 39.06% revenue share in 2023 due to several key factors. High prevalence rates of dry eye syndrome, driven by aging populations and increased screen time, contribute significantly to market growth. The region benefits from advanced healthcare infrastructure, which supports the rapid adoption of innovative treatments and advanced diagnostic tools. Additionally, the strong market presence of leading pharmaceutical companies and a high rate of consumer awareness further boost market expansion.

U.S. Dry Eye Syndrome Treatment Market Trends

The dry eye syndrome treatment market in the U.S. held a significant share of the North American market in 2023 due to its high prevalence of dry eye conditions, driven by an aging population and extensive screen use. The country’s advanced healthcare system facilitates the rapid adoption of innovative treatments and cutting-edge diagnostics.

Europe Dry Eye Syndrome Treatment Market Trends

The Europe dry eye syndrome treatment market is experiencing notable growth due to increasing awareness of dry eye disease and advancements in treatment options. Factors driving this growth include a rising aging population, which is more susceptible to dry eye conditions, and improvements in diagnostic tools. Additionally, the expansion of online pharmacies and the growing availability of innovative therapies contribute to market expansion. Supportive regulatory environments and increased investment in healthcare infrastructure also play a key role in driving the growth of the dry eye syndrome treatment market in Europe.

The dry eye syndrome treatment market in the UK is a major player in the region due to high disease prevalence, advanced healthcare infrastructure, and increasing public awareness. Additionally, significant investments in research and development, coupled with a strong presence of key pharmaceutical companies and accessible treatment options, contribute to its prominence and growth.

Germany dry eye syndrome treatment market is growing due to its advanced healthcare infrastructure, which supports early diagnosis and effective management of the condition. The country's robust research and development capabilities drive innovation in treatment options, while a high level of patient awareness and accessibility to a range of therapeutic products further fuel market expansion. Germany's strong healthcare system enhances overall treatment outcomes and market growth.

Asia Pacific Dry Eye Syndrome Treatment Market Trends

The dry eye syndrome treatment market in Asia Pacific is experiencing robust growth due to increasing urbanization, rising awareness about eye health, and a growing aging population. Improved access to healthcare services and advancements in treatment options further drive market expansion. The region’s expanding pharmaceutical infrastructure and rising prevalence of dry eye syndrome contribute to the robust demand for effective therapies.

China dry eye syndrome treatment market is expanding rapidly due to a large and growing population, increased urbanization, and rising awareness about eye health. Enhanced healthcare infrastructure and improved access to advanced treatment options further support this growth. The increasing prevalence of dry eye syndrome, driven by factors such as screen time and environmental conditions, also contributes to the rapid market expansion.

The dry eye syndrome treatment market in Japan is set to grow rapidly due to an aging population, increased prevalence of dry eye conditions, and heightened awareness of eye health. Advances in medical technology and the availability of innovative treatments further drive market growth. Additionally, Japan’s well-developed healthcare system and strong regulatory framework facilitate the introduction and adoption of new therapies.

Latin America Dry Eye Syndrome Treatment Market Trends

The Latin America dry eye syndrome treatment market is set to grow rapidly due to increasing awareness of eye health and the rising prevalence of dry eye conditions. Improved healthcare infrastructure and access to advanced treatments are contributing to this growth. Additionally, expanding pharmaceutical capabilities and investments in medical research are enhancing the availability of effective therapies, driving market expansion in the region.

The dry eye syndrome treatment market in Brazil is notably expanding due to the increasing prevalence of dry eye conditions, driven by urbanization and aging populations. Enhanced awareness, improved healthcare access, and a growing demand for effective treatments are further propelling market growth. Additionally, advancements in local healthcare infrastructure contribute to better diagnosis and management of the condition.

Middle East and Africa Dry Eye Syndrome Treatment Market Trends

The MEA dry eye syndrome treatment market holds major growth opportunities, as a majority of the market remains underserved with limited access to advanced treatments. Increasing healthcare investments, rising awareness, and a growing prevalence of dry eye conditions are driving demand for innovative therapies. Expanding healthcare infrastructure and improving diagnostic capabilities further support market growth, positioning the MEA region as a promising area for future development.

The dry eye syndrome treatment market in Saudi Arabia is expanding rapidly due to increased healthcare investments and rising awareness of eye conditions. Enhanced diagnostic capabilities and a growing emphasis on improving patient care are also contributing to market growth. Additionally, expanding healthcare infrastructure and better access to advanced treatments are driving demand in the region.

Key Dry Eye Syndrome Treatment Company Insights

The competitive scenario in the dry eye syndrome treatment market is highly competitive, with key players such as Novartis AG, AbbVie, Inc., Sun Pharmaceutical Industries Ltd., and Santen Pharmaceutical Co., Ltd. holding significant positions. These companies are undertaking various strategies such as new product development, collaborations, acquisitions, mergers, and regional expansion to serve the unmet needs of their customers.

Recent Developments

• In May 2024, Nordic Pharma, Inc. launched LACRIFILL Canalicular Gel, a novel dry eye treatment cleared by the FDA. This cross-linked hyaluronic acid gel temporarily blocks tear drainage by occluding the canalicular system, allowing natural tears to bathe the eyes. Administered via a simple in-office procedure, it lasts for six months and is reimbursed under CPT code 68761. Nordic Pharma is showcasing LACRIFILL at Kiawah Eye 2024, highlighting its potential to enhance ophthalmic practices. Nordic Pharma, part of SEVER Life Sciences, focuses on specialty pharmaceuticals and has a global presence.

• In June 2024, Oculis reported Phase 2b positive results for licaminlimab, anti-TNFα eye drop, shows significant improvement in multiple DED signs. The drug, effective in patients with a specific TNFR1 genetic biomarker, demonstrated rapid and notable reduction in corneal inflammation. Licaminlimab was well tolerated with similar side effects to a vehicle. The company plans to finalize Phase 3 development following FDA discussions. This precision medicine approach, targeting a genetic biomarker, could transform DED treatment, addressing the current dissatisfaction with existing therapies.

• In July 2023, Novaliq and Harrow announced Harrow's acquisition of U.S. and Canadian commercial rights to VEVYE 0.1%. VEVYE is a water-free, non-preserved cyclosporine product for dry eye disease, approved by the FDA in May 2023. It uniquely addresses both signs and symptoms of the condition with a twice-daily dosing regimen. Clinical trials demonstrate its efficacy and tolerability. Novaliq also secured a positive CHMP opinion for Vevizye in Europe and is pursuing regulatory review for CyclASol. Harrow will launch VEVYE in the U.S. later this year.

• In June 2023, Senju Pharmaceutical and Novaliq partnered to develop, manufacture, and market NOV03, a water-free, preservative-free eye drop for dry eye disease in Japan. NOV03, which targets tear evaporation by forming a lipid layer, is already approved in the U.S. and under review in China. This agreement includes upfront and milestone payments for Novaliq, plus royalties on sales in Japan. Novaliq also recently secured FDA approval for VEVYE, a cyclosporine-based dry eye treatment.

Dry Eye Syndrome Treatment Market Report Scope

Global Dry Eye Syndrome Treatment Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global dry eye syndrome treatment market report based on the type, drug, product, dosage form, sales channel, distribution channel, and region.

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Cyclosporine

  • Topical Corticosteroids

  • Artificial Tears

  • Punctal Plugs

    • Removable

    • Dissolvable

  • Oral Omega Supplements

  • Others

• Drug Outlook (Revenue, USD Million, 2018 - 2030)

  • Restasis

  • Xiidra

  • Cequa

  • Eysuvis

  • Tyrvaya

  • Others

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Evaporative Dry Eye Syndrome

  • Aqueous Deficient Dry Eye Syndrome

• Dosage Form Outlook (Revenue, USD Million, 2018 - 2030)

  • Gels

  • Eye solutions

  • Capsules & Tablets

  • Eye drops

  • Ointments

• Sales Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Prescription

  • OTC

• Distribution Channel Outlook (Revenue, USD Million, 2018 -2030)

  • Hospital Pharmacies

  • Online Pharmacies

  • Retail Pharmacies

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Norway

    • Denmark

    • Sweden

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

    • Mexico

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait